Arcus Biosciences (RCUS) Competitors

$14.82
-0.68 (-4.39%)
(As of 12:35 PM ET)

RCUS vs. ANIP, KURA, MORF, AKRO, DAWN, GYRE, EWTX, ARDX, ZLAB, and IRWD

Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include ANI Pharmaceuticals (ANIP), Kura Oncology (KURA), Morphic (MORF), Akero Therapeutics (AKRO), Day One Biopharmaceuticals (DAWN), Gyre Therapeutics (GYRE), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Zai Lab (ZLAB), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.

Arcus Biosciences vs.

ANI Pharmaceuticals (NASDAQ:ANIP) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability.

ANI Pharmaceuticals has a net margin of 3.86% compared to ANI Pharmaceuticals' net margin of -262.39%. Arcus Biosciences' return on equity of 18.06% beat ANI Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals3.86% 18.06% 8.38%
Arcus Biosciences -262.39%-57.17%-25.80%

ANI Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Comparatively, 13.8% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ANI Pharmaceuticals received 244 more outperform votes than Arcus Biosciences when rated by MarketBeat users. Likewise, 64.59% of users gave ANI Pharmaceuticals an outperform vote while only 64.41% of users gave Arcus Biosciences an outperform vote.

CompanyUnderperformOutperform
ANI PharmaceuticalsOutperform Votes
425
64.59%
Underperform Votes
233
35.41%
Arcus BiosciencesOutperform Votes
181
64.41%
Underperform Votes
100
35.59%

ANI Pharmaceuticals has higher revenue and earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANI Pharmaceuticals$486.82M2.86$18.78M$0.8478.64
Arcus Biosciences$117M11.51-$307M-$4.15-3.57

ANI Pharmaceuticals currently has a consensus target price of $80.00, indicating a potential upside of 21.10%. Arcus Biosciences has a consensus target price of $41.25, indicating a potential upside of 175.74%. Given ANI Pharmaceuticals' higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than ANI Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Arcus Biosciences
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

In the previous week, ANI Pharmaceuticals had 12 more articles in the media than Arcus Biosciences. MarketBeat recorded 17 mentions for ANI Pharmaceuticals and 5 mentions for Arcus Biosciences. ANI Pharmaceuticals' average media sentiment score of 0.36 beat Arcus Biosciences' score of 0.15 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ANI Pharmaceuticals
4 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcus Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

ANI Pharmaceuticals beats Arcus Biosciences on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCUS vs. The Competition

MetricArcus BiosciencesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$1.35B$6.43B$4.82B$17.40B
Dividend YieldN/A3.07%5.47%3.56%
P/E Ratio-3.577.90185.8121.98
Price / Sales11.51299.992,314.8411.48
Price / CashN/A29.1345.6817.62
Price / Book2.405.594.644.89
Net Income-$307M$139.22M$102.53M$963.51M
7 Day Performance-0.07%-1.16%-0.21%1.97%
1 Month Performance-9.80%-9.28%-6.33%-2.33%
1 Year Performance-23.25%0.53%9.38%89.77%

Arcus Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANIP
ANI Pharmaceuticals
4.7415 of 5 stars
$66.14
+0.8%
$80.00
+21.0%
+67.4%$1.39B$486.82M78.74642Analyst Report
Insider Selling
KURA
Kura Oncology
3.2144 of 5 stars
$18.73
+3.0%
$28.28
+51.0%
+70.3%$1.43BN/A-9.00142Analyst Report
News Coverage
MORF
Morphic
3.8268 of 5 stars
$28.75
+0.9%
$61.00
+112.2%
-35.9%$1.44B$520,000.00-8.24121Positive News
AKRO
Akero Therapeutics
3.6204 of 5 stars
$21.00
+1.0%
$37.71
+79.6%
-54.6%$1.45BN/A-7.3755Analyst Report
Positive News
DAWN
Day One Biopharmaceuticals
3.2879 of 5 stars
$16.64
+8.2%
$39.83
+139.4%
+21.5%$1.45BN/A-6.99155Analyst Report
Insider Selling
News Coverage
High Trading Volume
GYRE
Gyre Therapeutics
0.3698 of 5 stars
$15.94
-0.1%
N/AN/A$1.36B$113.45M-0.77593Positive News
EWTX
Edgewise Therapeutics
1.5299 of 5 stars
$15.65
+3.8%
$31.20
+99.4%
+105.4%$1.46BN/A-9.9188Analyst Report
News Coverage
ARDX
Ardelyx
3.8462 of 5 stars
$6.39
-1.8%
$12.69
+98.6%
+29.1%$1.49B$124.46M-21.30267Upcoming Earnings
ZLAB
Zai Lab
1.8494 of 5 stars
$15.12
+0.9%
$64.22
+324.8%
-58.0%$1.50B$266.72M-4.382,175Gap Up
IRWD
Ironwood Pharmaceuticals
3.9931 of 5 stars
$8.31
+3.1%
$19.80
+138.3%
-22.7%$1.30B$442.73M-1.28267

Related Companies and Tools

This page (NYSE:RCUS) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners